Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
复制标题
DOI：
10.1089/cbr.2013.1531
复制
发表时间：
2014-02-01
影响因子：
3.4
通讯作者：
Alvarez, Ronald
中科院分区：
文献类型：
--
作者：
Meredith, Ruby F.;Torgue, Julien;Alvarez, Ronald
Purpose: Study distribution, pharmacokinetics, and safety of intraperitoneal (IP) Pb-212-TCMC-trastuzumab in patients with HER-2-expressing malignancy. Experimental Design: IP Pb-212-TCMC-trastuzumab was delivered, after 4mg/kg intravenous (IV) trastuzumab, to 3 patients with HER-2-expressing cancer who had failed standard therapies. Patients were monitored for toxicity and pharmacokinetics/dosimetry parameters. Results: Imaging studies after 0.2mCi/m(2) (7.4MBq/m(2)) show little redistribution out of the peritoneal cavity and no significant uptake in major organs. Peak blood level of the radiolabeled antibody, determined by decay corrected counts, was 6 months showed no evidence of agent-related toxicity. Conclusions: Pharmacokinetics and imaging after 0.2mCi/m(2) IP Pb-212-TCMC-trastuzumab in patients with HER-2-expressing malignancy showed minimal distribution outside the peritoneal cavity, 6% urinary excretion, and good tolerance.
